(Q40463049)

English

A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer.

scientific article published on December 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Ursula A. Matulonis

3

object named as

Ursula A Matulonis

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

author name string

Anna Berkenblit

1

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Michael V Seiden

2

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Richard T Penson

4

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Carolyn N Krasner

5

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Maria Roche

6

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Lisa Mezzetti

7

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Tina Atkinson

8

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Stephen A Cannistra

9

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

language of work or name

0 references

publication date

1 December 2004

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

95

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

624-631

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Cancer of the ovary

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.028

7 January 2021

Treatment of recurrent ovarian cancer: increasing options--"recurrent" results

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.028

7 January 2021

Recurrent ovarian cancer: evidence-based treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.028

7 January 2021

Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.028

7 January 2021

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.028

7 January 2021

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.028

7 January 2021

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.028

7 January 2021

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.028

7 January 2021

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.028

7 January 2021

Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.028

7 January 2021

Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.028

7 January 2021

A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.028

7 January 2021

A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.028

7 January 2021

Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.028

7 January 2021

Effects of Taxotere on murine and human tumor cell lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.028

7 January 2021

Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of Taxol

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.028

7 January 2021

Role of Docetaxel in the Treatment of Newly Diagnosed Advanced Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.028

7 January 2021

Progress in the management of gynecologic cancer: consensus summary statement

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.028

7 January 2021

Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.028

7 January 2021

Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.028

7 January 2021

A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: a Japanese cooperative study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.028

7 January 2021

Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.028

7 January 2021

Docetaxel administered on a weekly basis for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.028

7 January 2021

Weekly administration of docetaxel for symptomatic metastatic hormone‐refractory prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.028

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.028

7 January 2021

Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.028

7 January 2021

Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.028

7 January 2021

Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.028

7 January 2021

Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.028

7 January 2021

Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.028

7 January 2021

Docetaxel extravasation causing significant delayed tissue injury

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.028

7 January 2021

Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of müllerian origin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.08.028

7 January 2021

Identifiers

10.1016/J.YGYNO.2004.08.028

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40463049&oldid=2114086696"